Skip to content
U.S. Transhumanist Party – Official Website
  • Home
  • Posts
  • Values
  • Platform
  • Leadership
  • Advisors
  • Candidates
  • Highlights
  • FAQ
  • States & Allies
  • Free Membership
  • Facebook
  • Twitter
  • Search Icon

U.S. Transhumanist Party – Official Website

U.S. Transhumanist Party – PUTTING SCIENCE, HEALTH, & TECHNOLOGY AT THE FOREFRONT OF AMERICAN POLITICS

Study Shows Telomerase Gene Therapy Does Not Increase Cancer Risk – Article by Steve Hill

Study Shows Telomerase Gene Therapy Does Not Increase Cancer Risk – Article by Steve Hill

June 21, 2019 Steve Hill Comments 0 Comment

Steve Hill


Editor’s Note: The U.S. Transhumanist Party features this article by our guest Steve Hill, originally published by the Life Extension Advocacy Foundation (LEAF) on August 27, 2018. This article takes another step forward toward clearing up a common misconception that many scientists and laypeople hold, i.e., the notion that extending telomeres causes cancer. Mr. Hill cited a recent article published in the journal PLOS Genetics, in which researchers found there to be no increase in cancer, even when telomeres were extended in mice from cancer-prone mouse strains. Hopefully this article will help researchers reevaluate this misconception so this very important age-reversal research will be advanced much faster.

~ Bobby Ridge, Assistant Editor, June 20, 2019

Researchers have demonstrated that telomerase gene therapy does not increase the risk of cancer, even in strains of mice that are particularly susceptible to cancer [1].

A tale of telomeres

Short telomeres trigger cellular senescence and are thought to be one of the primary hallmarks of aging, which has led to various researchers seeking ways to restore the telomeres in order to prevent cells from dying and to encourage division and tissue regeneration. We won’t go over the basics of telomeres and how they influence aging  here, but if you would like to learn more, check out our telomeres article, which explains it all.

Ever since Dr. Maria Blasco and her team at the Spanish National Cancer Research Centre (CNIO) first used telomerase gene therapy in mice back in 2012, a debate has raged about the potential of telomerase for regenerating tissue and reversing some aspects of aging versus the risk of it causing cancer.

Despite the concerns, it has proved effective against infarction by spurring regeneration of cardiac tissue and in treating aplastic anaemia and idiopathic pulmonary fibrosis in mice; all of these conditions are associated with critically short telomeres.

The CNIO’s Telomeres and Telomerase Group, which conducted the new study, has been investigating the potential of using telomerase therapy to treat age-related diseases for many years. Its 2012 publication featured a specially developed gene therapy that used an adeno-associated virus (AAV) to deliver a payload to cells that reactivated the telomerase gene, which can restore lost telomeres by creating the telomerase enzyme, and it appeared to delay and reverse certain aspects of aging [2].

Its AAV therapy is special in that the vectors do not integrate into the genomes of the target cells. Therefore, the telomerase activation only lasts for a few cell cycles before its effects cease. This transient activation of telomerase makes for a safety net, as unlimited cell division is only a step away from cancer.

Abstract

Short and dysfunctional telomeres are sufficient to induce a persistent DNA damage response at chromosome ends, which leads to the induction of senescence and/or apoptosis and to various age-related conditions, including a group of diseases known as “telomere syndromes”, which are provoked by extremely short telomeres owing to germline mutations in telomere genes. This opens the possibility of using telomerase activation as a potential therapeutic strategy to rescue short telomeres both in telomere syndromes and in age-related diseases, in this manner maintaining tissue homeostasis and ameliorating these diseases. In the past, we generated adeno-associated viral vectors carrying the telomerase gene (AAV9-Tert) and shown their therapeutic efficacy in mouse models of cardiac infarct, aplastic anemia, and pulmonary fibrosis. Although we did not observe increased cancer incidence as a consequence of Tert overexpression in any of those models, here we set to test the safety of AAV9-mediated Tert overexpression in the context of a cancer prone mouse model, owing to expression of oncogenic K-ras. As control, we also treated mice with AAV9 vectors carrying a catalytically inactive form of Tert, known to inhibit endogenous telomerase activity. We found that overexpression of Tert does not accelerate the onset or progression of lung carcinomas, even when in the setting of a p53-null background. These findings indicate that telomerase activation by using AAV9-mediated Tert gene therapy has no detectable cancer-prone effects in the context of oncogene-induced mouse tumors.

More support for telomerase gene therapy

Despite this safety measure, the medical use of telomerase therapy has been held back due to concerns of cancer risk, so the researchers at CNIO set out to see if this concern is justified.

To do this, they used this gene therapy in a mouse model that is at high risk of lung cancer. Their results showed that activating the telomerase gene via their gene therapy does not increase the risk of developing cancer, not even in this cancer-prone mouse strain.

These findings suggest that this gene therapy appears to be safe even in a pro-cancer environment. The authors chose this cancer-prone mouse strain to create a “killer experiment”, which creates a worst-case scenario that tests a hypothesis to its limit; if the hypothesis holds true despite the extreme scenario, it shows that the hypothesis is good. Because this therapy did not increase cancer risk in this extremely vulnerable mouse population, it demonstrates that telomerase gene therapy is possibly safe enough to use in humans.

The road ahead

The safety and utility of telomerase therapy is becoming more apparent with each passing year. The purpose of this new study was to demonstrate the plausibility of using telomerase to safely treat many diseases that currently have no cure, such as pulmonary fibrosis, and to help speed up its progress into human clinical trials.

Conclusion

The potential of telomerase gene therapy has long been debated amid cancer concerns, but this experiment suggests that those concerns are unfounded. There is no doubt that telomerase can and does regenerate tissue when it is delivered via gene therapy and that it does reverse various aspects of aging in multiple models.

Can we safely use what some people describe as a double-edged sword and apply it the fight against aging? This experiment strongly suggests that yes, we can.

Literature

[1] Muñoz-Lorente, M. A., Martínez, P., Tejera, Á., Whittemore, K., Moisés-Silva, A. C., Bosch, F., & Blasco, M. A. (2018). AAV9-mediated telomerase activation does not accelerate tumorigenesis in the context of oncogenic K-Ras-induced lung cancer. PLoS genetics, 14(8), e1007562.

[2] de Jesus, B. B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012). Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO molecular medicine, 4(8), 691-704.

Steve Hill serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.


Guest Articles
AAV, adeno-associated virus, aging, cancer, CNIO, gene therapy, LEAF, Life Extension Advocacy Foundation, Life Extension Advocacy Foundation (LEAF), longevity, Maria Blasco, mice, mouse, Spanish National Cancer Research Centre, Steve Hill, telomerase, telomeres

Post navigation

PREVIOUS
From Darwinian Greed to Altruistic Greed: the Strangest Period So Far in Our Planet’s History – Article by Hilda Koehler
NEXT
Meet the Naked Mole-Rat: Impervious to Pain and Cancer, and Lives Ten Times Longer Than It Should – Article by Ewan St. John Smith

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Social Media

Constitution of the U.S. Transhumanist Party

Transhumanist Bill of Rights – Version 3.0

U.S. Transhumanist Party Facebook Feed

Free Transhumanist Symbols

Guidelines for Community Conduct

SUBMIT A POST

LEV: The Game

Subject Categories

    - Life Extension
    - Artificial Intelligence
    - Space Colonization
    - Robotics
    - Biotechnology
    - Nanotechnology
    - Autonomous Vehicles
    - 3D Printing
    - Cryptocurrencies
    - Vertical Farming
    - Universal Basic Income
    - Existential Risk
    - Rationality

Hashtags

    #USTranshumanistParty, #TranshumanistParty, #TranshumanistPolitics, #TomRoss2024, #RossTwedt2024

Recent Posts

  • Why Is Trump So Intent on Sending Illegal Immigrant Noncriminals to Prison Camps in El Salvador? – Article by Alex Nowrasteh
  • Tribute to John Kerecz (1961 – 2025)
  • The Copenhagen Consensus – How to Feed the Hungry – Article by Zach Richardson
  • The Issue of Food – Article by Luis Arroyo
  • Results of Platform Vote #9 and Vote on Proposals on Investigations and Emergency Declarations; Adopted Sections of the U.S. Transhumanist Party Constitution
  • Official Ballot Options for Platform Vote #9 and Proposals on Investigations and Emergency Declarations
  • Gennady Stolyarov I and Gennady Stolyarov II Discuss the Progress of Information Technology (2019)
  • Immortality: My Quest and Reasons for Seeking an Indefinite Lifespan – Article by Albi Ndoni
  • U.S. Transhumanist Party General Discussion Thread for 2025
  • U.S. Transhumanist Party Statement on the Murder of Brian Thompson
  • News Regarding THPedia, the Transhumanist Encyclopedia for Everyone – Invitation to Contribute – Statement by Gennady Stolyarov II
  • The Transhumanist Council: A Worthy Effort for a New Umbrella Transhumanist Organization
  • Report on the Montana Right to Try Act – Analysis by Shamar White
  • U.S. Transhumanist Party Comments on the Citizen Petition by Age Reversal Unity to Declare Aging a Disease
  • U.S. Transhumanist Party Chairman’s Eighth Anniversary Message
  • U.S. Transhumanist Party Statement on the Outcome of the 2024 U.S. Presidential Election
  • Preliminary Member-Reported Write-In Totals for Tom Ross and Daniel Twedt in the 2024 U.S. Presidential Election
  • U.S. Transhumanist Party and Nevada Transhumanist Party Positions on 2024 Nevada Ballot Questions
  • Where to Write In Tom Ross for President of the United States – and How to Make Sure Your Vote Counts
  • Celebration of U.S. Transhumanist Party 10th Anniversary and International Longevity Month

Recent Comments

  • Tamara Tamas on Tribute to John Kerecz (1961 – 2025)
  • R. Nicholas Starr on U.S. Transhumanist Party General Discussion Thread for 2025
  • Luis Arroyo on Tribute to John Kerecz (1961 – 2025)
  • shamar on U.S. Transhumanist Party General Discussion Thread for 2025
  • Gennady Stolyarov II on U.S. Transhumanist Party General Discussion Thread for 2025

Archives

  • June 2025 (1)
  • May 2025 (1)
  • March 2025 (3)
  • February 2025 (1)
  • January 2025 (3)
  • December 2024 (2)
  • November 2024 (6)
  • October 2024 (3)
  • September 2024 (2)
  • August 2024 (5)
  • July 2024 (4)
  • June 2024 (3)
  • May 2024 (1)
  • March 2024 (1)
  • February 2024 (1)
  • January 2024 (8)
  • October 2023 (11)
  • September 2023 (6)
  • August 2023 (1)
  • July 2023 (4)
  • May 2023 (3)
  • April 2023 (3)
  • March 2023 (2)
  • February 2023 (12)
  • January 2023 (23)
  • December 2022 (2)
  • November 2022 (2)
  • October 2022 (3)
  • August 2022 (3)
  • July 2022 (2)
  • May 2022 (6)
  • March 2022 (3)
  • February 2022 (4)
  • January 2022 (7)
  • December 2021 (11)
  • November 2021 (4)
  • October 2021 (5)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (3)
  • June 2021 (2)
  • May 2021 (6)
  • April 2021 (7)
  • March 2021 (4)
  • February 2021 (5)
  • January 2021 (6)
  • December 2020 (10)
  • November 2020 (4)
  • October 2020 (2)
  • September 2020 (1)
  • August 2020 (4)
  • July 2020 (5)
  • June 2020 (6)
  • May 2020 (3)
  • April 2020 (3)
  • March 2020 (6)
  • February 2020 (1)
  • January 2020 (6)
  • December 2019 (3)
  • November 2019 (2)
  • October 2019 (9)
  • September 2019 (10)
  • August 2019 (12)
  • July 2019 (18)
  • June 2019 (17)
  • May 2019 (12)
  • April 2019 (8)
  • March 2019 (12)
  • February 2019 (7)
  • January 2019 (13)
  • December 2018 (9)
  • November 2018 (5)
  • October 2018 (9)
  • September 2018 (5)
  • August 2018 (10)
  • July 2018 (13)
  • June 2018 (14)
  • May 2018 (8)
  • April 2018 (8)
  • March 2018 (10)
  • February 2018 (15)
  • January 2018 (17)
  • December 2017 (8)
  • November 2017 (17)
  • October 2017 (19)
  • September 2017 (11)
  • August 2017 (11)
  • July 2017 (16)
  • June 2017 (15)
  • May 2017 (10)
  • April 2017 (7)
  • March 2017 (8)
  • February 2017 (16)
  • January 2017 (8)
  • December 2016 (6)
  • November 2016 (5)

Categories

  • Allied Projects
  • Announcements
  • Art
  • Candidates
  • Debate
  • Discussion Panels
  • Distributed Computing
  • Exposure Periods
  • Foreign Ambassadors
  • General Discussion
  • Guest Articles
  • Inclusion
  • Interviews
  • Legislative Analysis
  • Official Ballots
  • Petitions
  • Platform
  • Presentations
  • Press Releases
  • Research
  • Sample Ballots
  • Science Fiction
  • Statements
  • Tolerance
  • Virtual Enlightenment Salons
  • Vote Results
  • Working Groups

Victor Run Virtual Race – June 4-6, 2021

Historical Archive – 2020 U.S. Presidential Ticket – Charlie Kam and Liz Parrish


© 2025   Copyright - U.S. Transhumanist Party - All Rights Reserved | WordPress design: Art Ramon Paintings